Safety Concerns Prompt Pause of Magrolimab Trials
Unknown authors
Abstract
Gilead paused enrollment in trials of its anti-CD47 therapy magrolimab following suspicions of a safety issue experienced by patients with acute myeloid leukemia or myelodysplastic syndrome who received it in combination with the chemotherapeutic agent azacitidine.
Topics & Concepts
Myeloid leukemiaMedicineIntensive care medicineClinical trialLeukemiaMyelodysplastic syndromesMEDLINEMyeloidMedical emergencyPatient safetyPhagocytosis and Immune RegulationCAR-T cell therapy researchBiosimilars and Bioanalytical Methods